A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Social Anxiety Disorder.
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs JNJ 42165279 (Primary)
- Indications Social phobia
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 02 Jun 2017 Planned primary completion date changed from 2 Apr 2018 to 10 Jul 2018.
- 07 Feb 2017 Planned End Date changed from 1 Apr 2018 to 1 Jul 2018.
- 07 Feb 2017 Status changed from not yet recruiting to recruiting.